Candida albicans Antibody, IgM

Candida albicans Antibody, IgM (also known as a Candida antibody assay or candidiasis serology) is used as an adjunct in the assessment of suspected Candida infection. It helps characterize recent or primary exposure by identifying IgM antibodies to C. albicans and can be followed over time to observe serologic trends during therapy. Results are correlated with history, examination, and direct detection methods—such as microscopy, culture, molecular assays, and antigen testing—because colonization may produce seropositivity, and sensitivity is reduced in the early 1–2 week window after exposure and in immunosuppressed patients.

Candida albicans is a commensal yeast of skin and mucosal surfaces that can cause mucocutaneous disease or progress to invasive candidiasis under permissive conditions. Laboratory evaluation encompasses potassium hydroxide (KOH) microscopy, wet mounts for vulvovaginitis, culture, molecular tests (PCR), antigen detection, and serology. Serologic assays detect host antibodies formed in response to Candida antigens. IgM is typically the earliest antibody detected after a primary encounter with C. albicans, with peak levels developing within 1–2 weeks and declining as infection resolves. Upon re-exposure, IgG rises quickly, whereas the IgM response is comparatively attenuated. Because mucosal colonization is common and can stimulate antibody production, an isolated IgM-positive result does not distinguish colonization from clinically significant infection and functions as supportive evidence for mucocutaneous disease, secondary to clinical assessment and direct microscopy. Species-level identification remains clinically relevant due to variable antifungal susceptibilities; IgM assays directed at C. albicans do not detect non-albicans Candida species. In invasive candidiasis, no single diagnostic test is definitive; IgM serology may contribute within a multimodal strategy but is limited by reduced sensitivity in immunosuppressed patients and by the 1–2 week delay required to mount a detectable antibody response.